Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...
Watson Clinic Center for Cancer Care and Research, Lakeland, Florida, United States
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Novartis Investigative site, Buenos Aires, Argentina
University of Kentucky, Lexington, Kentucky, United States
Novartis Investigative Site, Ulm, Germany
Park Nicollet Cancer Center, Saint Louis Park, Minnesota, United States
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Hopital Cochin, Paris, France
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Meeker County Memorial Hospital, Litchfield, Minnesota, United States
St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
Memorial Hospital, Carthage, Illinois, United States
Novartis Investigative Site, Tochigi, Japan
Novartis investigative Site, Tokyo, Japan
Kantonsspital Winterthur, Winterthur, Switzerland
Klinik Hirslanden, Zurich, Switzerland
Universitaetsspital-Basel, Basel, Switzerland
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.